Global Radiopharmaceuticals-Nuclear Medicine Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Radiopharmaceuticals/ Nuclear Medicine Market Report Description:
Global radiopharmaceuticals/nuclear medicine market report gives comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies radiopharmaceuticals//nuclear medicine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the radiopharmaceuticals/nuclear medicine market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.
Global Radiopharmaceuticals/Nuclear Medicine Market:
Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. Market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radio therapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted into increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radio immunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
North America accounts for larger revenue share in global radiopharmaceuticals market
North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
COMPETITION ASSESSMENT
Key players profiles in the global Radiopharmaceuticals market include:
KEY FINDINGS OF THE REPORT:
By Product Type
Global radiopharmaceuticals/nuclear medicine market report gives comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies radiopharmaceuticals//nuclear medicine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the radiopharmaceuticals/nuclear medicine market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.
Global Radiopharmaceuticals/Nuclear Medicine Market:
Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. Market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radio therapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted into increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radio immunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
North America accounts for larger revenue share in global radiopharmaceuticals market
North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
COMPETITION ASSESSMENT
Key players profiles in the global Radiopharmaceuticals market include:
- Advanced Accelerator Applications S.A. (France)
- Bayer AG (Germany)
- Bracco Imaging S.p.A (Italy)
- Cardinal Health, Inc. (U.S.)
- Eli Lilly and Co. (U.S.)
- GE Healthcare (U.S.)
- IBA Molecular Imaging (Belgium)
- Jubilant Life Sciences Ltd (India)
- Lantheus Medical Imaging, Inc. (U.S.)
- Mallinckrodt plc (Ireland)
- Navidea Biopharmaceutical (U.S.)
- Nordion, Inc. (Canada)
- Siemens Healthineers (Germany)
KEY FINDINGS OF THE REPORT:
- Global Radiopharmaceuticals market expanding at 8.9% CAGR over 2017 to 2023 to reach market value of US$ 8,564 Mn by 2023
- Based on product type, diagnostic radiopharmaceuticals accounted for larger market revenue share in 2016 owing to wider application in various diagnostic procedures across the regions and expected to grow at significant rate
- Oncology application segment accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period owing to growing prevalence of various cancers
- Players are focusing on production of radiopharmaceuticals to expand market presence in global radiopharmaceuticals market.
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
By Product Type
- Diagnostic Radiopharmaceuticals
- SPECT Radiopharmaceuticals
- PET Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
- Beta Emitters
- Alpha emitters
- Brachytherapy
- Others
- Oncology
- Neurological disorders
- Cardiovascular diseases
- Thyroid
- Others
- Oral
- Inhalation
- Parenteral
- Hospitals
- Clinics
- Diagnostic Centers
- Research Institutes
- North America
- U.S
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
- Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
1. RESEARCH METHODOLOGY
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET DYNAMICS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET ANALYSIS, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals)
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY APPLICATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oncology
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Neurological disorders
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Cardiovascular diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Thyroid
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Others
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY ROUTE OF ADMINISTRATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Oral
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Inhalation
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Parenteral
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY END USER ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Hospitals
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Clinics
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Diagnostic Centers
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.4. Research Institutes
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
10. RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. North America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.1.1. Diagnostic Radiopharmaceuticals
10.1.1.1.1. SPECT Radiopharmaceuticals
10.1.1.1.2. PET Radiopharmaceuticals
10.1.1.2. Therapeutic Radiopharmaceuticals
10.1.1.2.1. Beta Emitters
10.1.1.2.2. Alpha emitters
10.1.1.2.3. Brachytherapy
10.1.1.2.4. Others
10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.2.1. Oncology
10.1.2.2. Neurological disorders
10.1.2.3. Cardiovascular diseases
10.1.2.4. Thyroid
10.1.2.5. Others
10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.3.1. Oral
10.1.3.2. Inhalation
10.1.3.3. Parenteral
10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.4.1. Hospitals
10.1.4.2. Clinics
10.1.4.3. Diagnostic Centers
10.1.4.4. Research Institutes
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.2. Europe Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.2.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.1.1. Diagnostic Radiopharmaceuticals
10.2.1.1.1. SPECT Radiopharmaceuticals
10.2.1.1.2. PET Radiopharmaceuticals
10.2.1.2. Therapeutic Radiopharmaceuticals
10.2.1.2.1. Beta Emitters
10.2.1.2.2. Alpha emitters
10.2.1.2.3. Brachytherapy
10.2.1.2.4. Others
10.2.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.2.1. Oncology
10.2.2.2. Neurological disorders
10.2.2.3. Cardiovascular diseases
10.2.2.4. Thyroid
10.2.2.5. Others
10.2.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.3.1. Oral
10.2.3.2. Inhalation
10.2.3.3. Parenteral
10.2.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.4.1. Hospitals
10.2.4.2. Clinics
10.2.4.3. Diagnostic Centers
10.2.4.4. Research Institutes
10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.5.1. U.K
10.2.5.2. Germany
10.2.5.3. France
10.2.5.4. Italy
10.2.5.5. Spain
10.2.5.6. Russia
10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.3.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.1.1. Diagnostic Radiopharmaceuticals
10.3.1.1.1. SPECT Radiopharmaceuticals
10.3.1.1.2. PET Radiopharmaceuticals
10.3.1.2. Therapeutic Radiopharmaceuticals
10.3.1.2.1. Beta Emitters
10.3.1.2.2. Alpha emitters
10.3.1.2.3. Brachytherapy
10.3.1.2.4. Others
10.3.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.2.1. Oncology
10.3.2.2. Neurological disorders
10.3.2.3. Cardiovascular diseases
10.3.2.4. Thyroid
10.3.2.5. Others
10.3.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.3.1. Oral
10.3.3.2. Inhalation
10.3.3.3. Parenteral
10.3.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.4.1. Hospitals
10.3.4.2. Clinics
10.3.4.3. Diagnostic Centers
10.3.4.4. Research Institutes
10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.5.1. Japan
10.3.5.2. China
10.3.5.3. India
10.3.5.4. ASEAN
10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.4.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.1.1. Diagnostic Radiopharmaceuticals
10.4.1.1.1. SPECT Radiopharmaceuticals
10.4.1.1.2. PET Radiopharmaceuticals
10.4.1.2. Therapeutic Radiopharmaceuticals
10.4.1.2.1. Beta Emitters
10.4.1.2.2. Alpha emitters
10.4.1.2.3. Brachytherapy
10.4.1.2.4. Others
10.4.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.2.1. Oncology
10.4.2.2. Neurological disorders
10.4.2.3. Cardiovascular diseases
10.4.2.4. Thyroid
10.4.2.5. Others
10.4.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.3.1. Oral
10.4.3.2. Inhalation
10.4.3.3. Parenteral
10.4.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.4.1. Hospitals
10.4.4.2. Clinics
10.4.4.3. Diagnostic Centers
10.4.4.4. Research Institutes
10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.5.1. Brazil
10.4.5.2. Mexico
10.4.5.3. Argentina
10.4.5.4. Venezuela
10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.5.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.1.1. Diagnostic Radiopharmaceuticals
10.5.1.1.1. SPECT Radiopharmaceuticals
10.5.1.1.2. PET Radiopharmaceuticals
10.5.1.2. Therapeutic Radiopharmaceuticals
10.5.1.2.1. Beta Emitters
10.5.1.2.2. Alpha emitters
10.5.1.2.3. Brachytherapy
10.5.1.2.4. Others
10.5.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.2.1. Oncology
10.5.2.2. Neurological disorders
10.5.2.3. Cardiovascular diseases
10.5.2.4. Thyroid
10.5.2.5. Others
10.5.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.3.1. Oral
10.5.3.2. Inhalation
10.5.3.3. Parenteral
10.5.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.4.1. Hospitals
10.5.4.2. Clinics
10.5.4.3. Diagnostic Centers
10.5.4.4. Research Institutes
10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.5.1. Gulf Cooperation Council (GCC) Countries
10.5.5.2. Israel
10.5.5.3. South Africa
10.5.5.4. Rest of MEA
11. COMPETITION LANDSCAPE
11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
11.2.1. Advanced Accelerator Applications S.A. (France)
11.2.2. Bayer AG (Germany)
11.2.3. Bracco Imaging S.p.A (Italy)
11.2.4. Cardinal Health, Inc. (U.S.)
11.2.5. Eli Lilly and Co. (U.S.)
11.2.6. GE Healthcare (U.S.)
11.2.7. IBA Molecular Imaging (Belgium)
11.2.8. Jubilant Life Sciences Ltd (India)
11.2.9. Lantheus Medical Imaging, Inc. (U.S.)
11.2.10. Mallinckrodt plc (Ireland)
11.2.11. Navidea Biopharmaceutical (U.S.)
11.2.12. Nordion, Inc. (Canada)
11.2.13. Siemens Healthineers (Germany)
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET DYNAMICS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET ANALYSIS, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals)
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY APPLICATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oncology
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Neurological disorders
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Cardiovascular diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Thyroid
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Others
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY ROUTE OF ADMINISTRATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Oral
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Inhalation
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Parenteral
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY END USER ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Hospitals
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Clinics
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Diagnostic Centers
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.4. Research Institutes
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
10. RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. North America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.1.1. Diagnostic Radiopharmaceuticals
10.1.1.1.1. SPECT Radiopharmaceuticals
10.1.1.1.2. PET Radiopharmaceuticals
10.1.1.2. Therapeutic Radiopharmaceuticals
10.1.1.2.1. Beta Emitters
10.1.1.2.2. Alpha emitters
10.1.1.2.3. Brachytherapy
10.1.1.2.4. Others
10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.2.1. Oncology
10.1.2.2. Neurological disorders
10.1.2.3. Cardiovascular diseases
10.1.2.4. Thyroid
10.1.2.5. Others
10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.3.1. Oral
10.1.3.2. Inhalation
10.1.3.3. Parenteral
10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.4.1. Hospitals
10.1.4.2. Clinics
10.1.4.3. Diagnostic Centers
10.1.4.4. Research Institutes
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.2. Europe Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.2.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.1.1. Diagnostic Radiopharmaceuticals
10.2.1.1.1. SPECT Radiopharmaceuticals
10.2.1.1.2. PET Radiopharmaceuticals
10.2.1.2. Therapeutic Radiopharmaceuticals
10.2.1.2.1. Beta Emitters
10.2.1.2.2. Alpha emitters
10.2.1.2.3. Brachytherapy
10.2.1.2.4. Others
10.2.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.2.1. Oncology
10.2.2.2. Neurological disorders
10.2.2.3. Cardiovascular diseases
10.2.2.4. Thyroid
10.2.2.5. Others
10.2.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.3.1. Oral
10.2.3.2. Inhalation
10.2.3.3. Parenteral
10.2.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.4.1. Hospitals
10.2.4.2. Clinics
10.2.4.3. Diagnostic Centers
10.2.4.4. Research Institutes
10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.5.1. U.K
10.2.5.2. Germany
10.2.5.3. France
10.2.5.4. Italy
10.2.5.5. Spain
10.2.5.6. Russia
10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.3.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.1.1. Diagnostic Radiopharmaceuticals
10.3.1.1.1. SPECT Radiopharmaceuticals
10.3.1.1.2. PET Radiopharmaceuticals
10.3.1.2. Therapeutic Radiopharmaceuticals
10.3.1.2.1. Beta Emitters
10.3.1.2.2. Alpha emitters
10.3.1.2.3. Brachytherapy
10.3.1.2.4. Others
10.3.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.2.1. Oncology
10.3.2.2. Neurological disorders
10.3.2.3. Cardiovascular diseases
10.3.2.4. Thyroid
10.3.2.5. Others
10.3.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.3.1. Oral
10.3.3.2. Inhalation
10.3.3.3. Parenteral
10.3.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.4.1. Hospitals
10.3.4.2. Clinics
10.3.4.3. Diagnostic Centers
10.3.4.4. Research Institutes
10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.5.1. Japan
10.3.5.2. China
10.3.5.3. India
10.3.5.4. ASEAN
10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.4.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.1.1. Diagnostic Radiopharmaceuticals
10.4.1.1.1. SPECT Radiopharmaceuticals
10.4.1.1.2. PET Radiopharmaceuticals
10.4.1.2. Therapeutic Radiopharmaceuticals
10.4.1.2.1. Beta Emitters
10.4.1.2.2. Alpha emitters
10.4.1.2.3. Brachytherapy
10.4.1.2.4. Others
10.4.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.2.1. Oncology
10.4.2.2. Neurological disorders
10.4.2.3. Cardiovascular diseases
10.4.2.4. Thyroid
10.4.2.5. Others
10.4.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.3.1. Oral
10.4.3.2. Inhalation
10.4.3.3. Parenteral
10.4.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.4.1. Hospitals
10.4.4.2. Clinics
10.4.4.3. Diagnostic Centers
10.4.4.4. Research Institutes
10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.5.1. Brazil
10.4.5.2. Mexico
10.4.5.3. Argentina
10.4.5.4. Venezuela
10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.5.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.1.1. Diagnostic Radiopharmaceuticals
10.5.1.1.1. SPECT Radiopharmaceuticals
10.5.1.1.2. PET Radiopharmaceuticals
10.5.1.2. Therapeutic Radiopharmaceuticals
10.5.1.2.1. Beta Emitters
10.5.1.2.2. Alpha emitters
10.5.1.2.3. Brachytherapy
10.5.1.2.4. Others
10.5.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.2.1. Oncology
10.5.2.2. Neurological disorders
10.5.2.3. Cardiovascular diseases
10.5.2.4. Thyroid
10.5.2.5. Others
10.5.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.3.1. Oral
10.5.3.2. Inhalation
10.5.3.3. Parenteral
10.5.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.4.1. Hospitals
10.5.4.2. Clinics
10.5.4.3. Diagnostic Centers
10.5.4.4. Research Institutes
10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.5.1. Gulf Cooperation Council (GCC) Countries
10.5.5.2. Israel
10.5.5.3. South Africa
10.5.5.4. Rest of MEA
11. COMPETITION LANDSCAPE
11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
11.2.1. Advanced Accelerator Applications S.A. (France)
11.2.2. Bayer AG (Germany)
11.2.3. Bracco Imaging S.p.A (Italy)
11.2.4. Cardinal Health, Inc. (U.S.)
11.2.5. Eli Lilly and Co. (U.S.)
11.2.6. GE Healthcare (U.S.)
11.2.7. IBA Molecular Imaging (Belgium)
11.2.8. Jubilant Life Sciences Ltd (India)
11.2.9. Lantheus Medical Imaging, Inc. (U.S.)
11.2.10. Mallinckrodt plc (Ireland)
11.2.11. Navidea Biopharmaceutical (U.S.)
11.2.12. Nordion, Inc. (Canada)
11.2.13. Siemens Healthineers (Germany)
